Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$14.76
-0.6%
$13.94
$7.58
$21.44
$190.11M1.623,325 shs17,200 shs
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$3.32
+5.4%
$2.76
$0.80
$12.68
$210.75M8.3622,886 shs29,068 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$5.20
-1.3%
$6.08
$4.50
$11.45
$157.67M0.95161,278 shs160,722 shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.15
$0.00
$0.12
$0.25
$147.97M0.884.33 million shs2.37 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-0.61%+2.64%+0.07%-15.66%+32.50%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
+4.76%+1.54%+13.79%+5.77%+73.68%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-1.33%-12.01%-13.19%-29.54%-39.53%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%+2.97%-26.60%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.2652 of 5 stars
3.52.00.00.02.43.30.6
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/AN/AN/AN/AN/AN/AN/AN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
1.5105 of 5 stars
3.31.00.00.02.62.50.6
Zomedica Corp. stock logo
ZOM
Zomedica
0.3707 of 5 stars
0.02.00.00.03.41.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$36.00143.90% Upside
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/AN/AN/AN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
2.50
Moderate Buy$9.5082.69% Upside
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/A

Current Analyst Ratings

Latest ZOM, GLSI, IXHL, and LFCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.52 per shareN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$930K226.62N/AN/A$0.89 per share3.73
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$103.27M1.53N/AN/A($0.14) per share-37.14
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M5.87N/AN/A$0.24 per share0.63

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$8.89M-$0.72N/AN/AN/AN/A-117.99%-113.35%8/19/2024 (Estimated)
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-$13.45MN/A0.00N/AN/AN/AN/A10/29/2024 (Estimated)
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$99.56M-$3.35N/AN/AN/AN/AN/AN/A8/29/2024 (Estimated)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.04N/AN/A-143.67%-8.62%-8.17%N/A

Latest ZOM, GLSI, IXHL, and LFCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2024Q1 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.20-$0.19+$0.01-$0.19N/AN/A
5/15/2024Q3 2024
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/A-$0.38-$0.38-$0.38N/AN/A
5/9/2024Q1 2024
Zomedica Corp. stock logo
ZOM
Zomedica
N/A-$0.01-$0.01-$0.01N/A$6.26 million    
4/15/2024Q4 2023
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A-$0.21-$0.21-$0.21N/AN/A
4/1/2024Q4 2023
Zomedica Corp. stock logo
ZOM
Zomedica
N/A-$0.01-$0.01N/A$7.00 million$7.34 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/AN/AN/AN/AN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
14.12
14.12
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/A
5.70
5.70
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
11.50
10.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
0.43%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
52.86%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
14.64%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
14.61%
Zomedica Corp. stock logo
ZOM
Zomedica
4.19%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
312.88 million6.07 millionNot Optionable
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
363.48 million54.19 millionNot Optionable
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
45930.32 million25.89 millionOptionable
Zomedica Corp. stock logo
ZOM
Zomedica
144979.95 million938.89 millionNot Optionable

ZOM, GLSI, IXHL, and LFCR Headlines

Recent News About These Companies

The 3 Most Undervalued Penny Stocks to Buy in June 2024

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Greenwich LifeSciences logo

Greenwich LifeSciences

NASDAQ:GLSI
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Incannex Healthcare logo

Incannex Healthcare

NASDAQ:IXHL
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
Lifecore Biomedical logo

Lifecore Biomedical

NASDAQ:LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Zomedica logo

Zomedica

NYSEAMERICAN:ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.